Abstract
Due to the clear trend of widening indication criteria for therapy with monoclonal antibodies active on the level of immunological synapse, the so-called checkpoint inhibitors, unanswered questions are appearing, regarding individualised medicine in the field of tumour immunology. In some cases, severe autoimmune toxicity and therapeutic response in only some 1/3 of the patients point towards the urgent need of identifying a suitable predictive and ideally prognostic biomarker for tumour immunotherapy.